Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

NCT03588975 is registered in ClinicalTrials.gov with Vericel Corporation as lead sponsor.

NCT NCT03588975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03588975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Lead sponsor
Vericel Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
October 24, 2018
Completion date
February 28, 2030
Enrollment
45 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

articular cartilage defect, articular cartilage disorder of knee, chondral defect, osteochondritis dissecans (ocd)